that's the best you got? here go take a look at this ...
"Merck Agrees to Buy Idenix for $3.85 Billion
Merck Pays Three Times Idenix's Value Friday in Bid to Expand Hepatitis C Portfolio
Merck agrees to buy hepatitis C treatment maker Idenix for $3.85 billion.
Merck agrees to buy hepatitis C treatment maker Idenix for $3.85 billion. Pictured, the sign outside the company's Summit, N.J., building. GETTY IMAGES
By PETER LOFTUS
Updated June 9, 2014 4:46 p.m. ET
Merck & Co.'s $3.85 billion deal to acquire a developer of hepatitis C drugs underscores the pharmaceutical industry's bet that improved medicines for the liver disease represent a large, long-term market opportunity.
Merck agreed to acquire Idenix Pharmaceuticals Inc. for $24.50 a share in cash, more than triple the stock's Friday closing price of $7.23 The premium was fueled by a competitive bidding process, according to Merck. Idenix shares soared to $24.03 in midday trading Monday, while Merck shares were unchanged at $57.85."
What do you think now?
Biopec -- Surely you're not saying that 100% of your portfolio is invested in SGYP, are you? What other stocks are you holding now?
The report uses data reported on FAERS data base (FDA adverse event reporting site) to show that Linzess is the primary suspect in 7 deaths, 85 hospitalizationsm, 16 diasbilties, and 10 adverse events that required intervention in just 3 years since its launch in 2013.
I saw the Phase Five report ... it was posted by @tgtxdough on twitter today. It's well documented and makes the case that Linzess should be taken off the market.
In another story this weekend, Barrons is reporting that their previous predictons have been complete and utter failures!! :))
" While the bird has chirped 3 times in 3 weeks we have yet to hear a full squawk."
biospec .... What on earth are you talking about?
The Rodman & Renshaw analyst have covered SGYP for several years now ... he knows this area very well ... knows the IRWD drug very well too ... with the $16 PT he's signalling that the FDA will approve plecantide and that it will take away market share from IRWD and additionally expand the market since the side effect profile for plecantide is a lot better!
Synergy Pharmaceuticals' (SGYP) Buy Rating and $16 PT Reiterated at Rodman & Renshaw
Rodman & Renshaw reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) with a price target of $16. Analyst Raghuram Selvaraju said he is highly confident in plecanatide's prospects.
"Early yesterday, Synergy Pharmaceuticals announced that the FDA had accepted its New Drug Application (NDA) for the company's lead drug candidate, plecanatide, for treatment of chronic idiopathic constipation (CIC) for review and had assigned a Prescription Drug User Fee Act (PDUFA) approval decision date of January 29, 2017. In our view, this filing acceptance by the FDA and formal assignation of an approval decision date constitutes a substantial milestone for the company. We remain highly confident in plecanatide's prospects and reiterate our Buy rating and 12-month price target of $16.00 per share on SGYP," said Selvaraju.
It seems highly undervalued compared to the ZS pharma buyout number. But it keeps getting hammered by the shorts and close to 52 week low! Anyone have a good explanation? Looking to build an entry position here.
gadzillionman -- you believe the FDA acceptance of SGYP's NDA on plecantide in CIC will NOT bounce the stock up at all ... why so?
What are the events you believe will move the stock up?